MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
In conclusion, MPT0G413 and BTZ synergistically inhibit MM viability, providing a framework for the clinical evaluation of combined therapies for MM. Introduction Multiple myeloma (MM) is a B cell malignancy characterized by the proliferation of bone marrow (BM) plasma cells and the production of large amounts of abnormal immunoglobulins (1) In the United States, it was estimated that 30,770 new MM cases would be diagnosed in 2018, accounting for 1.8% of newly diagnosed cancer cases (2). Furthermore, 12,770 MM-related deaths in 2018 accounted for an estimated 2.1% of all cancer deaths (2). In the past decade, MM treatment outcomes have improved since the approval of thalidomide-related immunomodulatory drugs and the proteasome inhibitor bortezomib by the FDA. Although MM patients have exhibited good responses to these agents (3), the incidence of relapse remains high (4, 5). Therefore, new agents are needed to ensure better long-term outcomes for such patients. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from lysines of histones and thus, act as gene transcription regulators (6). HDACs are considered attractive cancer therapeutic targets because changes in histone modification are frequently observed in human cancers, including MM. Accordingly, four small-molecule pan-HDAC inhibitors have been introduced for hematologic malignancies (7, 8). Recent clinical studies have evaluated the use of pan-HDAC inhibitors, such as vorinostat (suberoylanili...
AbstractBackgroundUntil now, there is no clear conclusion on the relationship between the surgical margin status after radical prostatectomy (RP) and prostate cancer-specific mortality (PCSM). Therefore, we conducted this systematic review and meta-analysis based on all eligible case –control studies.MethodsA systematic and comprehensive literature search was performed based on PUBMED and EMBASE to identify all of the potentially relevant publications which were published before September 2019. Hazard ratio (HR) for PCSM was independently extracted by two reviewers from all eligible studies. Pooled HR estimates with ...
ConclusionThe findings declare that inhibition ofPVT1 could be a new target in the treatment of AML-M0 and help to approach more to treatments with fewer side effects.
AbstractPurposeTo identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).Methods/PatientsWe explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.ResultsNLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069,p = 0.0034,p = 0.0160,p = 0.0063;p
ConclusionsIn conclusion, both the venous access catheter selection algorithm and the proposed recommendations aim to respond to the needs revealed in clinical practice and to become an integrable tool in electronic prescription systems to offer homogeneous criteria for action in cancer patients that require venous access, optimizing the use of available health resources with the highest safety and quality of life for the patient.
ConclusionmiR-1976 may serve as a promising non-invasive biomarker for the diagnosis of BC in the future.
AbstractIn this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Espa ñola de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination ofKRAS,NRAS andBRAF mutations and the convenience of determining the amplification of human epidermal growth factor ...
Expect another 30 to 40 years of increasing numbers of HPV-related oropharynx cancers, said an expert.Medscape Medical News
Publication date: Available online 20 September 2020Source: Materials Today: ProceedingsAuthor(s): Asmaa EL Mazyani, Mohammed Chafi, Mohamed Essahli
Publication date: December 2020Source: Materials Today Communications, Volume 25Author(s): Irfan Elahi, Syed Muhammad Alay-e-Abbas, Safdar Nazir, Ghulam Abbas, Waseem Akbar, Ali Shaukat, Muhammad Nawaz Tahir
More News: Academia | Acute Leukemia | Acute Myeloid Leukemia | Alzheimer's | Biology | Biomedical Science | Biotechnology | Brain | Burkitt Lymphoma | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Chemotherapy | Chia | Clinical Trials | Cutaneous T cell lymphoma | Denmark Health | Dexamethasone | Drugs & Pharmacology | Epithelial Cancer | Flavonoids | Fluoride | France Health | Genetics | Germany Health | Grants | Hematology | Israel Health | Italy Health | Leukemia | Lymphoma | Medical Ethics | Men | Middle East Health | Molecular Biology | Myeloma | Neurology | Neuroscience | Penicillin | Pfizer | Prednisone | Reproduction Medicine | Respiratory Medicine | Science | Sodium | Statistics | Stem Cell Therapy | Stem Cells | Study | T-cell Lymphoma | Taiwan Health | Thrombocytopenia | USA Health | Velcade | Weight Loss | Zinc